233 related articles for article (PubMed ID: 17639393)
1. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.
Meng F; Cai X; Duan J; Matteucci MG; Hart CP
Cancer Chemother Pharmacol; 2008 May; 61(6):953-63. PubMed ID: 17639393
[TBL] [Abstract][Full Text] [Related]
2. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
[TBL] [Abstract][Full Text] [Related]
3. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.
Nathwani SM; Butler S; Fayne D; McGovern NN; Sarkadi B; Meegan MJ; Lloyd DG; Campiani G; Lawler M; Williams DC; Zisterer DM
Cancer Chemother Pharmacol; 2010 Aug; 66(3):585-96. PubMed ID: 20020128
[TBL] [Abstract][Full Text] [Related]
4. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
Combes S; Barbier P; Douillard S; McLeer-Florin A; Bourgarel-Rey V; Pierson JT; Fedorov AY; Finet JP; Boutonnat J; Peyrot V
J Med Chem; 2011 May; 54(9):3153-62. PubMed ID: 21488686
[TBL] [Abstract][Full Text] [Related]
6. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M
Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672
[TBL] [Abstract][Full Text] [Related]
7. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity.
Bacher G; Nickel B; Emig P; Vanhoefer U; Seeber S; Shandra A; Klenner T; Beckers T
Cancer Res; 2001 Jan; 61(1):392-9. PubMed ID: 11196193
[TBL] [Abstract][Full Text] [Related]
8. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W
Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459
[TBL] [Abstract][Full Text] [Related]
9. Structure-based virtual screening of novel tubulin inhibitors and their characterization as anti-mitotic agents.
Kim ND; Park ES; Kim YH; Moon SK; Lee SS; Ahn SK; Yu DY; No KT; Kim KH
Bioorg Med Chem; 2010 Oct; 18(19):7092-100. PubMed ID: 20810285
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 4-Substituted Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors.
Cao D; Liu Y; Yan W; Wang C; Bai P; Wang T; Tang M; Wang X; Yang Z; Ma B; Ma L; Lei L; Wang F; Xu B; Zhou Y; Yang T; Chen L
J Med Chem; 2016 Jun; 59(12):5721-39. PubMed ID: 27213819
[TBL] [Abstract][Full Text] [Related]
11. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
13. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
[TBL] [Abstract][Full Text] [Related]
14. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
[TBL] [Abstract][Full Text] [Related]
15. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of new 2-methoxyestradiol derivatives: Potent inhibitors of angiogenesis and tubulin polymerization.
Sun M; Zhang Y; Qin J; Ba M; Yao Y; Duan Y; Liu H; Yu D
Bioorg Chem; 2021 Aug; 113():104988. PubMed ID: 34034135
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and characterization of potent microtubule inhibitors with dual anti-proliferative and anti-angiogenic activities.
Zhang H; Fang X; Meng Q; Mao Y; Xu Y; Fan T; An J; Huang Z
Eur J Med Chem; 2018 Sep; 157():380-396. PubMed ID: 30099258
[TBL] [Abstract][Full Text] [Related]
18. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
19. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
[TBL] [Abstract][Full Text] [Related]
20. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]